APNH.Y Stock Overview

Manufactures and supplies specialty and branded pharmaceutical products worldwide. More details

APNH.Y fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	1/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 30.2% below our estimate of its fair value

Earnings are forecast to grow 21.87% per year

Risk Analysis

Dividend of 2.07% is not well covered by free cash flows

Large one-off items impacting financial results

My Notes

Capture your thoughts, links and company narrative

Aspen Pharmacare Holdings Limited Competitors

Prestige Consumer Healthcare

NYSE:PBH

US$3.9b

Organon

NYSE:OGN

US$3.8b

Elanco Animal Health

NYSE:ELAN

US$5.7b

Corcept Therapeutics

NasdaqCM:CORT

US$5.4b

Price History & Performance

Summary of share price highs, lows and changes for Aspen Pharmacare Holdings
Historical stock prices
Current Share Price	R9.38
52 Week High	R13.69
52 Week Low	R8.93
Beta	0.61
1 Month Change	-2.82%
3 Month Change	-14.09%
1 Year Change	-14.98%
3 Year Change	-29.17%
5 Year Change	10.91%
Change since IPO	47.68%

Recent updates

Shareholder Returns

	APNH.Y	US Pharmaceuticals	US Market
7D	-0.5%	-1.5%	-2.4%
1Y	-15.0%	7.9%	23.4%

Return vs Industry: APNH.Y underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.

Return vs Market: APNH.Y underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is APNH.Y's price volatile compared to industry and market?
APNH.Y volatility
APNH.Y Average Weekly Movement	6.2%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: APNH.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine APNH.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1850	9,109	Stephen Saad	www.aspenpharma.com

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names.

Aspen Pharmacare Holdings Limited Fundamentals Summary

How do Aspen Pharmacare Holdings's earnings and revenue compare to its market cap?
APNH.Y fundamental statistics
Market cap	US$4.21b
Earnings (TTM)	US$240.35m
Revenue (TTM)	US$2.44b

17.5x

P/E Ratio

1.7x

P/S Ratio

Is APNH.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APNH.Y income statement (TTM)
Revenue	R44.71b
Cost of Revenue	R25.29b
Gross Profit	R19.42b
Other Expenses	R15.01b
Earnings	R4.40b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	9.91
Gross Margin	43.43%
Net Profit Margin	9.85%
Debt/Equity Ratio	42.3%

How did APNH.Y perform over the long term?

See historical performance and comparison

Dividends

2.1%

Current Dividend Yield

36%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 19:48
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aspen Pharmacare Holdings Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andre Bekker	Arqaam Capital Research Offshore S.A.L.
Boitshepo Seruwe	Avior Capital Markets
Simon Mather	Barclays